Skip to main content
Top
Published in: Inflammation 1/2014

01-02-2014

Mean Platelet Volume Seems To Be a Valuable Marker in Patients with Systemic Sclerosis

Authors: Serdar Soydinc, Ibrahim Halil Turkbeyler, Yavuz Pehlivan, Gulcimen Soylu, Mehmet Fatih Goktepe, Muhammed Bilici, Orhan Zengin, Bunyamin Kisacik, Ahmet Mesut Onat

Published in: Inflammation | Issue 1/2014

Login to get access

Abstract

The predictors for the development of cardiovascular diseases and peripheral arterial diseases in patients with systemic sclerosis (SSc) were not clearly established, and there is no specific study conducted to investigate the mean platelet volume (MPV) levels in SSc patients. Therefore, this study evaluates the MPV levels in SSc and possible relationship between SSc, its clinical features and activity/severity scores, and MPV. In total, 76 SSc patients (67 women and 9 men, mean age 50.44 ± 13.21 years) diagnosed according to the classification criteria of the American College of Rheumatology and 45 healthy volunteers were enrolled into study. Data relating to anamnesis, physical examination, MPV, erythrocyte sedimentation rate, C-reactive protein levels, electrocardiography, echocardiography, high-resolution computerized tomography findings, complaints, and treatment processes were recorded into the database. Of the total cases, 17 had (22.3 %) cardiac involvement, 45 had gastrointestinal involvement (59.2 %), 47 had (61.8 %) lung involvement, 31 (32 %) had finger flexion deformity, and 27 (35.5 %) had digital ulcers at the fingertips. The mean MPV levels of SSc patients were significantly higher than those of the control group (p = 0.008). The mean MPV levels of SSc patients with cardiac involvement, digital ulcers, and gangrene presence were significantly high, and lower in Ilomedin-receiving patients than in the Ilomedin naives (p < 0.05). A negative relationship was discovered between the mean MPV levels, Valentini score, and Disease Severity Index of the patients with systemic sclerosis (p = 0.006, r = −0.310; p = 0.047, r = −0.229). MPV levels were significantly elevated in SSc patients and they were negatively correlated with disease activity scores. Increased MPV levels would be a predictive marker in the diagnosis of macrovascular and microvascular disease involvement in SSc patients.
Literature
1.
go back to reference LeRoy, E.C. 1996. Systemic sclerosis. A vascular perspective. Rheumatic Diseases Clinics of North America 22: 675–694.CrossRef LeRoy, E.C. 1996. Systemic sclerosis. A vascular perspective. Rheumatic Diseases Clinics of North America 22: 675–694.CrossRef
2.
go back to reference Kahaleh, M.B., and E.C. Leroy. 1999. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31: 195–214.CrossRef Kahaleh, M.B., and E.C. Leroy. 1999. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31: 195–214.CrossRef
3.
go back to reference Kahaleh, M.B. 2004. Vascular involvement in systemic sclerosis (SSc). Clinical and Experimental Rheumatology 22: 19–23. Kahaleh, M.B. 2004. Vascular involvement in systemic sclerosis (SSc). Clinical and Experimental Rheumatology 22: 19–23.
4.
go back to reference Gear, A.R., and D. Camerini. 2003. Platelet chemokines and chemokine receptors: Linking hemostasis, inflammation, and host defense. Microcirculation 10: 335–350.CrossRef Gear, A.R., and D. Camerini. 2003. Platelet chemokines and chemokine receptors: Linking hemostasis, inflammation, and host defense. Microcirculation 10: 335–350.CrossRef
5.
go back to reference Weyrich, A.S., S. Lindemann, and G.A. Zimmerman. 2003. The evolving role of platelets in inflammation. Journal of Thrombosis and Haemostasis 1: 1897–1905.CrossRef Weyrich, A.S., S. Lindemann, and G.A. Zimmerman. 2003. The evolving role of platelets in inflammation. Journal of Thrombosis and Haemostasis 1: 1897–1905.CrossRef
6.
go back to reference Martin, J.F., T. Shaw, J. Heggie, and D.G. Penington. 1983. Measurement of the density of human platelets and its relationship to volume. British Journal of Haematology 54: 337–352.CrossRef Martin, J.F., T. Shaw, J. Heggie, and D.G. Penington. 1983. Measurement of the density of human platelets and its relationship to volume. British Journal of Haematology 54: 337–352.CrossRef
7.
go back to reference Martin, J.F., P.M.W. Bath, and M.L. Burr. 1991. Influence of platelet size on outcome after myocardial infarction. Lancet 338: 1409–1411.CrossRef Martin, J.F., P.M.W. Bath, and M.L. Burr. 1991. Influence of platelet size on outcome after myocardial infarction. Lancet 338: 1409–1411.CrossRef
8.
go back to reference Berger, J.S., L.H. Eraso, D. Xie, D. Sha, and E.R. Mohler 3rd. 2010. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999–2004. Atherosclerosis 213(2): 586–591.CrossRef Berger, J.S., L.H. Eraso, D. Xie, D. Sha, and E.R. Mohler 3rd. 2010. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999–2004. Atherosclerosis 213(2): 586–591.CrossRef
9.
go back to reference Pattanaik, D., M. Brown, and A.E. Postlethwaite. 2011. Vascular involvement in systemic sclerosis (scleroderma). Journal of Inflammation Research 4: 105–125.PubMedPubMedCentral Pattanaik, D., M. Brown, and A.E. Postlethwaite. 2011. Vascular involvement in systemic sclerosis (scleroderma). Journal of Inflammation Research 4: 105–125.PubMedPubMedCentral
10.
go back to reference Friedhoff, L.T., J.R. Seibold, H.C. Kim, and K.S. Simester. 1984. Serotonin induced platelet aggregation in systemic sclerosis. Clinical and Experimental Rheumatology 2: 119–123.PubMed Friedhoff, L.T., J.R. Seibold, H.C. Kim, and K.S. Simester. 1984. Serotonin induced platelet aggregation in systemic sclerosis. Clinical and Experimental Rheumatology 2: 119–123.PubMed
11.
go back to reference Postlethwaite, A.E., and T.M. Chiang. 2007. Platelet contributions to the pathogenesis of systemic sclerosis. Current Opinion in Rheumatology 19: 574–579.CrossRef Postlethwaite, A.E., and T.M. Chiang. 2007. Platelet contributions to the pathogenesis of systemic sclerosis. Current Opinion in Rheumatology 19: 574–579.CrossRef
12.
go back to reference Masi, A.T., T.A. Medsger, G.P. Rodnan, et al. 1980. Preliminary criteria for the classification of systemic sclerosis. Arthritis and Rheumatism 23: 581–590.CrossRef Masi, A.T., T.A. Medsger, G.P. Rodnan, et al. 1980. Preliminary criteria for the classification of systemic sclerosis. Arthritis and Rheumatism 23: 581–590.CrossRef
13.
go back to reference Clements, P., P. Lachenbruch, J. Seibold, et al. 1995. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. Journal of Rheumatology 22: 1281–1285. Clements, P., P. Lachenbruch, J. Seibold, et al. 1995. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. Journal of Rheumatology 22: 1281–1285.
14.
go back to reference Valentini, G., A. Della Rossa, S. Bombardieri, et al. 2001. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Annals of the Rheumatic Diseases 60: 592–598.CrossRef Valentini, G., A. Della Rossa, S. Bombardieri, et al. 2001. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Annals of the Rheumatic Diseases 60: 592–598.CrossRef
15.
go back to reference Medsger Jr., T.A., A.J. Silman, V.D. Steen, et al. 1999. A disease severity scale for systemic sclerosis: Development and testing. Journal of Rheumatology 26: 2159–2167. Medsger Jr., T.A., A.J. Silman, V.D. Steen, et al. 1999. A disease severity scale for systemic sclerosis: Development and testing. Journal of Rheumatology 26: 2159–2167.
16.
go back to reference Gawaz, M. 2004. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovascular Research 61: 498–511.CrossRef Gawaz, M. 2004. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovascular Research 61: 498–511.CrossRef
17.
go back to reference Anitua, E., I. Andia, B. Ardanza, P. Nurden, and A.T. Nurden. 2004. Autologous platelets as a source of proteins for healing and tissue regeneration. Thrombosis and Haemostasis 91: 4–15.CrossRef Anitua, E., I. Andia, B. Ardanza, P. Nurden, and A.T. Nurden. 2004. Autologous platelets as a source of proteins for healing and tissue regeneration. Thrombosis and Haemostasis 91: 4–15.CrossRef
18.
go back to reference Villeneuve, J., A. Block, M.C. Le Bousse-Kerdiles, S. Lepreux, P. Nurden, J. Ripoche, et al. 2009. Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins. Experimental Hematology 37: 849–856.CrossRef Villeneuve, J., A. Block, M.C. Le Bousse-Kerdiles, S. Lepreux, P. Nurden, J. Ripoche, et al. 2009. Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins. Experimental Hematology 37: 849–856.CrossRef
19.
go back to reference Yanaba, K., K. Takehara, and S. Sato. 2004. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: Association with lower frequency of pulmonary fibrosis. Annals of the Rheumatic Diseases 63: 583–587.CrossRef Yanaba, K., K. Takehara, and S. Sato. 2004. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: Association with lower frequency of pulmonary fibrosis. Annals of the Rheumatic Diseases 63: 583–587.CrossRef
20.
go back to reference Frenette, P.S., C.V. Denis, L. Weiss, K. Jurk, S. Subbarao, B. Kehrel, et al. 2000. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. Journal of Experimental Medicine 191: 1413–1422.CrossRef Frenette, P.S., C.V. Denis, L. Weiss, K. Jurk, S. Subbarao, B. Kehrel, et al. 2000. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. Journal of Experimental Medicine 191: 1413–1422.CrossRef
21.
go back to reference Kasper, B., and F. Petersen. 2011. Molecular pathways of platelet factor 4/CXCL4 signaling. European Journal of Cell Biology 90: 521–526.CrossRef Kasper, B., and F. Petersen. 2011. Molecular pathways of platelet factor 4/CXCL4 signaling. European Journal of Cell Biology 90: 521–526.CrossRef
22.
go back to reference Maeda, M., H. Kachi, and S. Mori. 1998. Ultrastructural observation of platelets from patients with progressive systemic sclerosis (PSS). Journal of Dermatology 25: 222–230.CrossRef Maeda, M., H. Kachi, and S. Mori. 1998. Ultrastructural observation of platelets from patients with progressive systemic sclerosis (PSS). Journal of Dermatology 25: 222–230.CrossRef
23.
go back to reference Allanore, Y., D. Borderie, C. Meune, H. Lemarechal, S. Weber, O.G. Ekindjian, et al. 2005. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Annals of the Rheumatic Diseases 64: 481–483.CrossRef Allanore, Y., D. Borderie, C. Meune, H. Lemarechal, S. Weber, O.G. Ekindjian, et al. 2005. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Annals of the Rheumatic Diseases 64: 481–483.CrossRef
24.
go back to reference Komura, K., S. Sato, M. Hasegawa, M. Fujimoto, and K. Takehara. 2004. Elevated circulating CD40L concentrations in patients with systemic sclerosis. Journal of Rheumatology 31: 514–519. Komura, K., S. Sato, M. Hasegawa, M. Fujimoto, and K. Takehara. 2004. Elevated circulating CD40L concentrations in patients with systemic sclerosis. Journal of Rheumatology 31: 514–519.
25.
go back to reference Herrick, A.L., K. Illingworth, A. Blann, C.R. Hay, S. Hollis, and M.I. Jayson. 1996. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Annals of the Rheumatic Diseases 55: 122–127.CrossRef Herrick, A.L., K. Illingworth, A. Blann, C.R. Hay, S. Hollis, and M.I. Jayson. 1996. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Annals of the Rheumatic Diseases 55: 122–127.CrossRef
26.
go back to reference Guiducci, S., J.H. Distler, A. Jungel, D. Huscher, L.C. Huber, B.A. Michel, et al. 2008. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism 58: 2845–2853.CrossRef Guiducci, S., J.H. Distler, A. Jungel, D. Huscher, L.C. Huber, B.A. Michel, et al. 2008. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism 58: 2845–2853.CrossRef
27.
go back to reference Fonseca, C., D. Abraham, and M. Ponticos. 2009. Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis. Current Vascular Pharmacology 7: 34–39.CrossRef Fonseca, C., D. Abraham, and M. Ponticos. 2009. Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis. Current Vascular Pharmacology 7: 34–39.CrossRef
28.
go back to reference Silveri, F., R. De Angelis, A. Poggi, S. Muti, G. Bonapace, F. Argentati, et al. 2001. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scandinavian Journal of Rheumatology 30: 290–296.CrossRef Silveri, F., R. De Angelis, A. Poggi, S. Muti, G. Bonapace, F. Argentati, et al. 2001. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scandinavian Journal of Rheumatology 30: 290–296.CrossRef
29.
go back to reference Polidoro, L., R. Barnabei, P. Giorgini, L. Petrazzi, C. Ferri, and G. Properzi. 2012. Platelet activation in patients with the Raynaud's Phenomenon. Internal Medicine Journal 42: 531–535.CrossRef Polidoro, L., R. Barnabei, P. Giorgini, L. Petrazzi, C. Ferri, and G. Properzi. 2012. Platelet activation in patients with the Raynaud's Phenomenon. Internal Medicine Journal 42: 531–535.CrossRef
30.
go back to reference Zaldivar, M.M., K. Pauels, P. von Hundelshausen, M.L. Berres, P. Schmitz, J. Bornemann, et al. 2010. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 51: 1345–1353.CrossRef Zaldivar, M.M., K. Pauels, P. von Hundelshausen, M.L. Berres, P. Schmitz, J. Bornemann, et al. 2010. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 51: 1345–1353.CrossRef
31.
go back to reference Dees, C., A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, et al. 2011. Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine 208: 961–972.CrossRef Dees, C., A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, et al. 2011. Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine 208: 961–972.CrossRef
32.
go back to reference Abou-Raya, A., S. Abou-Raya, and M. Helmii. 2008. Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. Journal of Rheumatology 35: 1801–1808. Abou-Raya, A., S. Abou-Raya, and M. Helmii. 2008. Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. Journal of Rheumatology 35: 1801–1808.
33.
go back to reference Matucci-Cerinic, M., and J.R. Seibold. 2008. Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford, England) 47: 46–47.CrossRef Matucci-Cerinic, M., and J.R. Seibold. 2008. Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford, England) 47: 46–47.CrossRef
34.
go back to reference Hak, A.E., E.W. Karlson, D. Feskanich, M.J. Stampfer, and K.H. Costenbader. 2009. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis and Rheumatism 61: 1396–1402.CrossRef Hak, A.E., E.W. Karlson, D. Feskanich, M.J. Stampfer, and K.H. Costenbader. 2009. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis and Rheumatism 61: 1396–1402.CrossRef
35.
go back to reference Balbaloglu O, Korkmaz M, Yolcu S, Karaaslan F, Beceren NG. 2013. Evaluation of mean platelet volume (MPV) levels in patients with synovitis associated with knee osteoarthritis. Platelets. doi:10.3109/09537104.2013.776162 Balbaloglu O, Korkmaz M, Yolcu S, Karaaslan F, Beceren NG. 2013. Evaluation of mean platelet volume (MPV) levels in patients with synovitis associated with knee osteoarthritis. Platelets. doi:10.​3109/​09537104.​2013.​776162
36.
go back to reference Kisacik, B., A. Tufan, U. Kalyoncu, O. Karadag, A. Akdogan, M.A. Ozturk, S. Kiraz, I. Ertenli, and M. Calguneri. 2008. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint, Bone, Spine 75: 291–294.CrossRef Kisacik, B., A. Tufan, U. Kalyoncu, O. Karadag, A. Akdogan, M.A. Ozturk, S. Kiraz, I. Ertenli, and M. Calguneri. 2008. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint, Bone, Spine 75: 291–294.CrossRef
37.
go back to reference Gasparyan, A.Y., A. Sandoo, A. Stavropoulos-Kalinoglou, and G.D. Kitas. 2010. Mean platelet volume in patients with rheumatoid arthritis: The effect of anti-TNF-α therapy. Rheumatology International 30: 1125–1129.CrossRef Gasparyan, A.Y., A. Sandoo, A. Stavropoulos-Kalinoglou, and G.D. Kitas. 2010. Mean platelet volume in patients with rheumatoid arthritis: The effect of anti-TNF-α therapy. Rheumatology International 30: 1125–1129.CrossRef
38.
go back to reference Stürzebecher, C.S. 1987. Effects of iloprost on platelet activation in vitro. In Prostacyclin and its stable analogue iloprost, ed. R.J. Gryglewski and G. Stock, 39–45. Berlin: Springer.CrossRef Stürzebecher, C.S. 1987. Effects of iloprost on platelet activation in vitro. In Prostacyclin and its stable analogue iloprost, ed. R.J. Gryglewski and G. Stock, 39–45. Berlin: Springer.CrossRef
Metadata
Title
Mean Platelet Volume Seems To Be a Valuable Marker in Patients with Systemic Sclerosis
Authors
Serdar Soydinc
Ibrahim Halil Turkbeyler
Yavuz Pehlivan
Gulcimen Soylu
Mehmet Fatih Goktepe
Muhammed Bilici
Orhan Zengin
Bunyamin Kisacik
Ahmet Mesut Onat
Publication date
01-02-2014
Publisher
Springer US
Published in
Inflammation / Issue 1/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9716-x

Other articles of this Issue 1/2014

Inflammation 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine